Can a custom mRNA vaccine keep ovarian cancer from coming back?

NCT ID NCT07724106

Not yet recruiting Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether a personalized mRNA vaccine called NeoOVSV, given alongside standard chemotherapy and an immunotherapy drug, can safely help prevent ovarian cancer from returning after surgery. The vaccine is designed to train the immune system to recognize and attack unique markers on a person's tumor. The study enrolls about 9 women with stage II or III ovarian cancer and will closely monitor side effects and immune responses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental mRNA-lipid nanoparticle vaccine called NeoOVSV, given with standard chemotherapy and a PD-1 antibody
What this could lead to: If it works, this approach could help prevent ovarian cancer from returning after surgery by training the immune system to attack remaining cancer cells.
What could go wrong: This is a very early, small Phase 1 trial with only 9 participants, so safety and effectiveness are not yet known. The vaccine may cause side effects like injection-site reactions, fever, or immune-related issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MRNA VACCINE OVARIAN CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.